Trial Profile
A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2017.
- 17 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.